Mikra Cellular Sciences Inc. ("Mikra"), a biosciences company driving breakthrough applications of bioactive compounds to positively impact human health and intervene before pharmaceuticals are necessary, today announced $8.5 million in funding from its parent company, Lifeist Wellness Inc. The funding will be used in part to market and meet Mikra's consumer demand for its first product, CELLFTM (pronounced "self"), engineered to increase cellular performance and improve one's "healthspan," as well as fuel Mikra's continuous product development. CELLF currently has a waitlist of 40,000+ consumers, all of whom will gain access to the product via pre-sale today.